TuHURA Biosciences, Inc. has announced plans to initiate a Phase 3 accelerated approval trial for its treatment IFx-2.0, targeting 40% enrollment by the end of 2025. The company has secured $12.5 million in commitments through a private offering and an additional $3.0 million from warrant exercises to support this initiative. The funding will also facilitate the acquisition and initiation of a Phase 2 trial in NPM1 mutated acute myeloid leukemia $(AML.AU)$ through the closing of a merger with Kineta, Inc. Currently, there are no results available from these studies, as the trials and acquisitions are in the planning and initiation stages.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.